Analyst Firms Increase Price Targets for DexCom (DXCM) Following Product Clearances and Market Expansion
Money

Analyst Firms Increase Price Targets for DexCom (DXCM) Following Product Clearances and Market Expansion

authorBy Vicki Robin
DateJun 22, 2026
Read Time2 min
This report details recent positive developments for DexCom, Inc., a leading company in continuous glucose monitoring systems. It highlights two major analyst firms' decisions to increase price targets for DXCM shares, driven by new product clearances and expanding market opportunities.

DexCom's Ascent: Innovation and Market Expansion Drive Investor Confidence

Piper Sandler Upgrades DexCom's Outlook

On June 15, 2026, Piper Sandler analyst Matt O'Brien adjusted the firm's price target for DexCom, Inc. (NASDAQ:DXCM) to $88, up from $75, while maintaining an 'Overweight' rating. This revision was based on updated financial models that better reflect the company's quarterly performance, official guidance, and market consensus. Piper Sandler cited improved clarity regarding DexCom's long-term product pipeline and upcoming catalysts, which are expected to fuel sustained, significant revenue growth.

FDA Greenlights Stelo for Broader Use

A significant milestone occurred on June 12, 2026, when the U.S. Food and Drug Administration (FDA) approved DexCom, Inc.'s (NASDAQ:DXCM) Stelo Glucose Biosensor System for over-the-counter sales, making it the first continuous glucose monitor available without a prescription for children aged two and older who do not use insulin. This follows the FDA's prior approval of Stelo OTC for adults aged 18 and above in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, underscored the FDA's dedication to fostering innovation for pediatric patients, highlighting the importance of this clearance.

TD Cowen Boosts Price Target for DexCom

Just two days prior, on June 10, 2026, TD Cowen analyst Joshua Jennings also increased his price target for DexCom, Inc. (NASDAQ:DXCM) to $95 from $75, reiterating a 'Buy' rating. Jennings emphasized DexCom's prominent role in expanding coverage for Type 2 Non-Insulin Treated (T2NIT) diabetes patients, noting that the company's CONNECT data package presents a compelling case for insurance providers. TD Cowen views DexCom as a significant market share gainer in the U.S. T2NIT segment, anticipating that enhanced access will benefit all industry participants given the substantial market potential.

DexCom's Role in Diabetes Management

DexCom, Inc. (NASDAQ:DXCM) is a key player in the design, development, and commercialization of continuous glucose monitoring systems. These innovative systems are vital for diabetes and metabolic health management, serving both domestic and international markets. The company's ongoing advancements and strategic market positioning underscore its importance in healthcare technology.

More Articles
Money
Amazon: A Leading Long-Term Investment Opportunity
Amazon continues to solidify its position as a top-tier long-term investment. Recent strategic moves include an expanded partnership with PennyMac Financial Services, leveraging AWS's AI capabilities for mortgage technology, and significant investments in European operations, robotics, and employee upskilling. These initiatives underscore Amazon's commitment to innovation and growth across diverse sectors, reinforcing its appeal to long-term investors.
By Dave RamseyJun 22, 2026
Money
Charles Schwab Witnesses Remarkable Growth in May with Record Net New Assets
Charles Schwab (SCHW) reported an exceptional May 2026, achieving a new record for core net new assets, which surged by 43% year-over-year to $49.9 billion. The firm's total client assets reached $13.14 trillion, reflecting a 27% increase from May 2025. Concurrently, new brokerage accounts saw a 37% rise, totaling 461,000, and daily average trades hit an unprecedented 11.8 million.
By JL CollinsJun 22, 2026
Money
Understanding the 'Rule of 55' for Early Retirement Account Access
Many individuals are unaware of a crucial exception to the standard retirement withdrawal age: the Rule of 55. This provision allows penalty-free access to 401(k) or 403(b) funds as early as age 55 under specific conditions, primarily when separating from service with an employer in the year you turn 55 or later. However, despite its potential benefits for early retirees, less than a third of eligible workers utilize this rule. This article explores the mechanics of the Rule of 55, its limitations, and considerations for those contemplating early withdrawals.
By Ramit SethiJun 22, 2026
Money
Johnson & Johnson Bolsters Vision Business with Major U.S. Manufacturing Investment
Johnson & Johnson is making a substantial investment exceeding $1 billion in Jacksonville, Florida, to enhance its Vision manufacturing, packaging, and distribution capabilities. This strategic move aims to expand U.S.-based production of ACUVUE contact lenses and fortify its supply chain resilience, reflecting a broader commitment to domestic operations and innovation in healthcare.
By Bola SokunbiJun 22, 2026
Money
Apple's AI Strategy: Integrating Intelligence Across Devices and Services
Apple has revealed its next-generation AI capabilities, dubbed Apple Intelligence, deeply integrating them into its ecosystem of devices including iPhone, iPad, Mac, and Apple Watch. This strategic move aims to enhance user experience by embedding advanced AI features within its existing hardware and software, rather than launching a standalone AI product. Siri, in particular, receives significant upgrades, enabling more contextual understanding and cross-app functionality.
By Mr. Money MustacheJun 22, 2026